BA and SB supplementation: Assigned Interventions: * Beta-alanine (BA) * Sodium bicarbonate (SB) Description: • Participants receive beta-alanine and sodium bicarbonate Intervention list \& supplementation details: 1. Beta-alanine (BA) * Form: Gelatin capsules * Substance: Pure beta-alanine * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Sodium bicarbonate (SB) * Form: Gelatin capsules * Substance: Pure sodium bicarbonate * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This group tests the combined effects of BA and SB
BA and PL2 supplementation: Participants in this intervention group will undergo chronic supplementation with beta-alanine (BA) and an inert placebo (PL2) matched to the sodium bicarbonate (SB) protocol. * Beta-alanine (pure, in gelatin capsules) will be administered at a total daily dose of 6.4 g, divided into four servings taken with meals, over a period of 28 consecutive days. * PL2 (placebo matched to SB, in gelatin capsules) will be administered from Day 21 to Day 28 of beta-alanine supplementation, at a daily dose of 0.3 g per kg of body mass, divided into three equal servings taken with meals. This group allows for evaluation of the isolated effects of BA supplementation when combined with a placebo comparator to SB
PL1 and SB supplementation: Assigned Interventions: * Placebo matched to BA (PL1) * Sodium bicarbonate (SB) Description: • Participants receive only sodium bicarbonate as the active compound and placebo capsules matching the BA protocol. Intervention list \& supplementation details: 1. Placebo matched to BA (PL1) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and dosing schedule to BA * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Sodium bicarbonate (SB) * Form: Gelatin capsules * Substance: Pure sodium bicarbonate * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This group tests the isolated effects of SB
PL1 and PL2 supplementation: Assigned Interventions: * Placebo matched to BA (PL1) * Placebo matched to SB (PL2) Description: • Participants receive two matched placebos. Intervention list \& supplementation details: 1. Placebo matched to BA (PL1) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and dosing schedule to BA * Daily dose: 6.4 g/day * Dosing schedule: Four equal servings taken with meals (breakfast, lunch, snack, dinner) * Supplementation period: days 1 to 28 2. Placebo matched to SB (PL2) * Form: Gelatin capsules * Substance: Inert substance matched in appearance and timing to SB * Daily dose: 0.3 g/kg body mass per day * Dosing schedule: Three equal servings taken with meals (breakfast, lunch, dinner) * Supplementation period: days 21 to 28 of BA or PL1 supplementation Rationale: • This serves as the control group for comparison with all active intervention arms.
This randomized, double-blind, placebo-controlled, parallel-group study aims to evaluate the potential synergistic effect of beta-alanine (BA) and sodium bicarbonate (SB) supplementation, compared to their separate administration or placebo (PL), on physical performance and selected blood biochemical markers in highly trained female basketball players.
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Sports Dietetics, Poznan University of Physical Education Poznań | Poznan | Wielkopolska | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07092930 on ClinicalTrials.gov ↗ ← All trials in Poland